![Lynn Lester](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lynn Lester
Plus aucun poste en cours
Profil
Lynn Lester worked as a Senior Vice President-Human Resources at MedImmune Ltd.
and as a Vice President-Human Resources at ApaTech Ltd.
She holds an MBA from the University of Leeds.
Anciens postes connus de Lynn Lester
Sociétés | Poste | Fin |
---|---|---|
ApaTech Ltd.
![]() ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Responsable des Ressources Humaines | - |
MedImmune Ltd.
![]() MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Responsable des Ressources Humaines | - |
Formation de Lynn Lester
University of Leeds | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 2 |
---|---|
MedImmune Ltd.
![]() MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
ApaTech Ltd.
![]() ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Health Technology |